Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Arab Journal of Gastroenterology. 2017; 18 (2): 98-103
em Inglês | IMEMR | ID: emr-189172

RESUMO

Background and study aims: Apoptosis represents a well-known mechanism of cell death involved in most chronic liver injuries. Our aim was to investigate the serum fragment level of cytokeratin 18 [CK18], M30, in asymptomatic hepatitis B virus [HBV] carriers and patients with chronic hepatitis B [CHB] and to evaluate the relationship between serum M30 levels and the severity of hepatic injury


Patients and methods: Asymptomatic HBV carriers [n = 169], patients with CHB [n = 100], and healthy control subjects [n = 43] were enrolled in the study. Serum CK18 [M30] levels were analysed in all subjects. Liver biopsy for histopathological assessment was performed in asymptomatic HBV carriers and in patients with CHB infection


Results: Serum CK18 [M30] levels were significantly higher in asymptomatic HBV carriers [198.77 +/- 77.62 U/L] than in healthy control subjects [146.92 +/- 40.18 U/L]. Patients with CHB [283.02 +/- 147.45 U/L] had significantly higher CK18 [M30] levels than asymptomatic HBV carriers [p = 0.001]. The diagnostic efficacy of CK18 [M30] levels in distinguishing patients with HBeAg-negative CHB from asymptomatic HBV carriers was found to be moderate [c-statistics: 0.695], and the diagnostic cut-off value of CK18 [M30] was 262 U/L [specificity: 85%, sensitivity: 48%, positive likelihood ratio: 3.35, and negative likelihood ratio: 0.60]. There was a positive correlation between serum CK18 [M30] levels and histological activity index scores in asymptomatic HBV carriers and patients with CHB


Conclusions: Serum CK18 [M30] levels may be a valuable indicator in distinguishing asymptomatic HBV carriers from patients with HBeAg-negative CHB when considered together with ALT and HBV-DNA levels


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Queratina-18/sangue , Infecções Assintomáticas , Vírus da Hepatite B , Hepatite B Crônica , Portador Sadio , Fragmentos de Peptídeos
2.
Medical Principles and Practice. 2003; 12 (3): 176-9
em Inglês | IMEMR | ID: emr-63883

RESUMO

To determine the prevalence and clinical impact of transfusion-transmitted virus [TTV] DNA in patients with chronic liver diseases in the Southeast Anatolia region of Turkey where hepatitis B and C viral infections are endemic. Subjects and Patients diagnosed with chronic liver disease by clinical, biochemical and histologic means were enrolled in the study. Serum samples of 60 patients [19 males, 41 females] with chronic liver diseases, and of 45 healthy volunteer blood donors as a control group were collected. The chronic liver disease group consisted of 11 patients with hepatitis B, 44 with hepatitis C and 5 with chronic liver disease of unknown etiology. Presence of TTV DNA was investigated by the polymerase chain reaction. Using a scoring system histological grading of inflammation and staging of fibrosis were performed only in the chronic hepatitis C group. TTV DNA was detected in 47 [78%] patients with chronic liver disease and 5 [11%] volunteers in the control group. The difference was statistically significant [p < 0.001]. Ten of the 11 [91%] patients with hepatitis B, 32 of 44 [73%] of those with hepatitis C-related chronic liver disease, and 5 of 5 [100%] of the patients with cryptogenic liver disease were positive for TTV DNA. TTV is highly prevalent in patients with chronic liver diseases in Southeast Anatolia, Turkey but no pathogenic effect attributable to TTV infection was detected


Assuntos
Humanos , Masculino , Feminino , Hepatopatias/virologia , Doença Crônica , Infecções/transmissão , Doenças Endêmicas , Infecções/virologia , Hepatite B/transmissão , Hepatite C/transmissão , Prevalência , Hepacivirus/patogenicidade , Vírus da Hepatite B/patogenicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA